GP方案对比GT方案一线治疗转移性三阴性乳腺癌的疗效研究  

Efficacy research of GP regimen compared with GT regimen in the first-line treatment of metastatic triple-negative breast cancer

作　　者：李红姬[1] 金载勇[1] LI Hong-ji, JIN Zai-yong.(Jilin Central Hospital, Jilin 132011, China)

机构地区：[1]吉林市中心医院,132011

出　　处：《中国实用医药》2018年第29期1-3,共3页China Practical Medicine

摘　　要：目的探讨GP方案对比GT方案一线治疗转移性三阴性乳腺癌的疗效。方法 90例转移性三阴性乳腺癌患者,根据治疗方法不同分为对照组及观察组,各45例。对照组给予GT方案一线治疗,观察组给予GP方案一线治疗。比较两组转移性三阴性乳腺癌控制率,治疗前后患者体力状态评分、卡氏健康评分、乳腺癌患者生命质量测定量表(FACT-B)评分,生存时间,药物不良反应发生情况。结果观察组转移性三阴性乳腺癌控制率66.67%高于对照组的44.44%,差异具有统计学意义(P<0.05)。治疗前,观察组患者FACT-B评分、卡氏健康评分、体力状态评分分别为(90.25±6.24)、(65.25±2.18)、(3.54±1.18)分,对照组患者FACT-B评分、卡氏健康评分、体力状态评分分别为(90.21±6.25)、(65.21±2.13)、(3.52±1.15)分,两组患者的FACT-B评分、卡氏健康评分、体力状态评分比较,差异均无统计学意义(P>0.05);治疗后,观察组患者FACT-B评分、卡氏健康评分、体力状态评分分别为(45.13±3.56)、(80.12±4.02)、(1.12±0.25)分,对照组患者FACT-B评分、卡氏健康评分、体力状态评分分别为(65.71±4.13)、(70.12±3.46)、(2.11±0.45)分,两组患者的FACT-B评分、卡氏健康评分、体力状态评分均较本组治疗前改善,且观察组改善程度优于对照组,差异均具有统计学意义(P<0.05)。观察组恶心呕吐、血小板降低发生率分别为66.67%、44.44%,高于对照组的44.44%、22.22%;脱发发生率为22.22%,低于对照组的46.67%,差异具有统计学意义(χ~2=4.500、5.000、5.954, P<0.05)。观察组患者生存时间为(35.11±2.41)个月,明显长于对照组的(30.14±2.25)个月,差异具有统计学意义(t=10.112,P<0.05)。结论 GP方案治疗转移性三阴性乳腺癌的应用效果确切,可更好控制病情,延长生存时间,提高生命质量,值得推广应用。Objective To investigate the efficacy of GP regimen compared with GT regimen in the firstline treatment of metastatic triple-negative breast cancer. Methods A total of 90 patients with metastatic triplenegative breast cancer were divided into control group and observation group according to different treatment methods, 45 cases in each group. The control group received first-line treatment with GT, the observation group received first-line treatment with GP. The control rate of metastatic triple-negative breast cancer, the patient physical status score, Karnofsky performance status score and functional assessment of cancer therapy-breast（FACT-B） score before and after treatment, survival time and incidence of adverse drug reactions between the two groups. Results The control rate of metastatic triple-negative breast cancer in the observation group was 66.67%, which was significantly higher than 44.44% in the control group, the difference was statistically significant（P〈0.05）. Before treatment, the FACT-B score, Karnofsky performance status score and physical status score of the observa tion group were（90.25±6.24） scores,（65.25±2.18） scores and（3.54±1.18） scores respectively, the FACT-B score, Karnofsky performance status score and physical status score of the control group were（90.21±6.25） scores,（65.21±2.13） scores and（3.52±1.15） scores respectively. There were no significant differences in the FACT-B score, Karnofsky performance status score and physical status score between the two groups before treatment（P〉0.05）. After treatment, the FACT-B score, Karnofsky performance status score and physical status score of the observation group were（45.13±3.56） scores,（80.12±4.02） scores and（1.12± 0.25） scores respectively, the FACT-B score, Karnofsky performance status score and physical status score of the control group were（65.71±4.13） scores,（70.12±3.46） scores and（2.11±0.45） scores respectively. The FACT-B score, Karnofsky performance status

关 键 词：GP方案 GT方案 一线治疗 转移性三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]